# Clinical Trials Data EGFR - Document 20

# First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT01646450

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients.\n\* Positive EGFR Mutation.\n\* No previous systemic anticancer therapy.\n\* Male and female patients aged over 70 years.\n\* Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site.\n\* Provision of written informed consent.\n\nExclusion Criteria:\n\n\* Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).\n\* Known severe hypersensitivity to icotinib or any of the excipients of this product.\n\* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "70 Years",  
"stdAges": [  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, a patient with an EGFR gene mutation could be eligible for the clinical trial, provided that they meet all other inclusion and exclusion criteria. Here's the reasoning:  
  
1. \*\*Inclusion Criteria\*\*:  
 - The trial requires participants to have a positive EGFR mutation, which the patient has.  
 - The patient must have recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB.  
 - The patient must be over 70 years old and must not have received previous systemic anticancer therapy.  
 - There should be at least one measurable lesion according to RECIST criteria.  
  
2. \*\*Provision of written informed consent\*\*: This is a standard requirement for participation in clinical trials.  
  
3. \*\*Exclusion Criteria\*\*:   
 - The patient must not have clinically active Interstitial Lung Diseases.  
 - They should have no known severe hypersensitivity to icotinib or any excipients of the product.  
 - There should be no other significant clinical disorder or laboratory finding making participation undesirable.  
  
If the patient meets all the inclusion criteria and none of the exclusion criteria, they would be eligible for the trial.